Global Targeted Alpha-particle Therapy Market Growth (Status and Outlook) 2024-2030

Global Targeted Alpha-particle Therapy Market Growth (Status and Outlook) 2024-2030

Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. It has the potential to provide highly targeted treatment, especially to microscopic tumour cells. Targets include leukemias, lymphomas, gliomas, melanoma, and peritoneal carcinomatosis. As in diagnostic nuclear medicine, appropriate radionuclides can be chemically bound to a targeting biomolecule which carries the combined radiopharmaceutical to a specific treatment point.

The global Targeted Alpha-particle Therapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Targeted Alpha-particle Therapy Industry Forecast” looks at past sales and reviews total world Targeted Alpha-particle Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Alpha-particle Therapy sales for 2023 through 2029. With Targeted Alpha-particle Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Alpha-particle Therapy industry.

This Insight Report provides a comprehensive analysis of the global Targeted Alpha-particle Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Alpha-particle Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Alpha-particle Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Alpha-particle Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Alpha-particle Therapy.

United States market for Targeted Alpha-particle Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Targeted Alpha-particle Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Targeted Alpha-particle Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Targeted Alpha-particle Therapy players cover Bayer, Orano Med, Oncoinvent AS, Perspective Therapeutics, Ablaze Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Alpha-particle Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Actinium-225
Astatine-211
Lead-212
Bismuth-213
Others

Segmentation by Application:
Immunotherapy
Peritoneal Carcinomas
Bone Metastases
Leukaemia
Melanomas
Solid Tumours

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Actinium-225
Astatine-211
Lead-212
Bismuth-213
Others

Segmentation by Application:
Immunotherapy
Peritoneal Carcinomas
Bone Metastases
Leukaemia
Melanomas
Solid Tumours

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Orano Med
Oncoinvent AS
Perspective Therapeutics
Ablaze Pharma
ARTBIO
Fusion Pharmaceuticals(AstraZeneca)
AlphaGen Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.